Pregnancy and Childbirth
Conditions
Interventions
Intravenous tranexemic Acid
Intravenous water for injection
Sponsors
Ofonere Chukwunonso Nnabuike
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: This will comprise all women; age greater or equal to 18 years, planned vaginal delivery, at term (greater or equal to 37 weeks of gestation), with singleton pregnancy, who will give informed consent
Exclusion criteria
Exclusion criteria: This will comprise women with history of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris, myocardial infarction, stroke) thrombosis, history of epilepsy or seizure, any known cardiovascular, renal, or liver disorders, autoimmune disease, sickle cell disease, severe hemorrhagic disease, placenta anomalies eg previa, abruption etc, hypertensive disorders in pregnancy eg pre-eclampsia, eclampsia, multiple pregnancy, in utero fetal death, administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery and women that have allergy to tranexamic acid.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure of this study is to estimate the total blood loss after vaginal delivery. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures include determining the incidence of PPH, the need for use of additional uterotonics and blood transfusion as well as the safety/side effect profile in the groups of women. | — |
Countries
Nigeria
Contacts
Public ContactIfeanyi onyekpa
Consultant
Outcome results
None listed